Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $1.2 million.

  • Fulcrum Therapeutics' Other Non-Current Assets changed 0.0% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.2 million for FY2024, which is 4027.85% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Other Non-Current Assets of $1.2 million as of Q3 2025, which was down 0.0% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Other Non-Current Assets ranged from a high of $2.1 million in Q4 2022 and a low of $1.1 million during Q1 2021
  • Moreover, its 5-year median value for Other Non-Current Assets was $1.1 million (2021), whereas its average is $1.2 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Other Non-Current Assets skyrocketed by 9276.56% in 2022, and later tumbled by 4027.85% in 2024.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' Other Non-Current Assets stood at $1.1 million in 2021, then skyrocketed by 92.77% to $2.1 million in 2022, then dropped by 4.47% to $2.0 million in 2023, then crashed by 40.28% to $1.2 million in 2024, then changed by 0.0% to $1.2 million in 2025.
  • Its Other Non-Current Assets was $1.2 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.2 million in Q1 2025.